|
|
|
|
| |
|
| |
|
|
https://mb.cision.com/Public/18595/logo/86a99b25f755738d_org.jpg
BIMZELX^=C2=AE bimekizumab Approved in Japan for the Treatment of Plaq=
ue Psoriasis, Generalized Pustular Psoriasis and Psoriatic Erythroderma
=C2=B7 The third approval for bimekizumab worldwide reinforces UCB=E2=80=99=
s commitment to bring new treatment options to the global dermatology commu=
nity
=C2=B7 Approval is... See more |
|
|
|
| |
|
| |
|
|
https://mb.cision.com/Public/18595/logo/86a99b25f755738d_org.jpg
Disposals of own shares
Brussels Belgium, 21 January 2022 =E2=80=93 20:00 CET =E2=80=93 regulat=
ed information
Disposal of own shares
In accordance with article 8:6 of the Royal Decree executing the Belgian Co=
de of Companies and Associations, UCB announces that, following exercises o=
f stock options by members... See more |
|
|
|
| |
|
| |
|
|
https://mb.cision.com/Public/18595/logo/86a99b25f755738d_org.jpg
Positive TopLine Results for BIMZELX^=C2=AE=E2=96=BCbimekizumab in Se=
cond Phase 3 Psoriatic Arthritis Study
=C2=B7 The BE COMPLETE study evaluated bimekizumab in adults with active ps=
oriatic arthritis who were inadequate responders or intolerant to antiTNF =
treatment
=C2=B7 BE COMPLETE is the second positive Phase... See more |
|
|
|
| |
|
| |
|
|
Le Groupe Econocom renforce sa gouvernance
Nominations
de Monsieur Laurent Roudil au poste d'Administrateur Délégué – CEO et de Monsieur Angel Benguigui au poste Directeur Général Délégué
Après une période d'assainissement et de consolidation... | |
Search :
